1. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma 
Howard Sofen, MD, Kenneth G. Gross, MD, Leonard H. Goldberg, MD, FRCP, Harry Sharata, MD, PhD, Tiffani K. Hamilton, MD, Barbara Egbert, MD, Benjamin Lyons, PhD, Jeannie Hou, MD, Ivor Caro, MD 
Journal of the American Academy of Dermatology 
Volume 73, Issue 1, Pages e1 (July 2015)
DOI: /j.jaad
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Treatment (Tx) interventions and assessments by cohort. ∗In patients who discontinued vismodegib Tx prematurely, the target lesion was removed with conventional excision and Mohs evaluation of margins was performed between weeks 13 and 15, or earlier if the investigator chose. †Patients who discontinued vismodegib before the completion of 8 weeks of Tx did not enter the 24-week observation period, but underwent excision and Mohs micrographic surgery between weeks 13 and 15; patients who discontinued between weeks 8 and 12 entered the observation period, and underwent excision and Mohs micrographic surgery at week 37. ‡Patients who discontinued early underwent target lesion excision and Mohs evaluation at week 20, or earlier if the investigator chose. CHC, Complete histologic clearance; D1, day 1; F/U, follow-up; PK, pharmacokinetic.
Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad )
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2 Patient disposition.
Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad )
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Case examples of patients treated with vismodegib. A, Complete histologic clearance after excision (patient 23036; white male, 59 years of age). B, Small focus of residual disease on histologic analysis after excision (patient 23056; white male, 57 years of age). BCC, Basal cell carcinoma; CR, complete response; PR, partial response.
Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad )
Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions